Genmab A/S Sponsored ADR (GMAB) vs Incyte Corporation (INCY)
Genmab A/S Sponsored ADR and Incyte Corporation are both Biotechnology companies. Incyte Corporation is the larger, with a market value of $25.5B against $20.8B — 1.2× the size. Incyte Corporation trades at the lower P/E: 15.2× against 27.8×. Incyte Corporation grew revenue faster over the last twelve months: 26.9% against 22.3%. Incyte Corporation has the higher net margin (27.7% vs 19.1%) and the higher return on invested capital (60.5% vs 6.99%). Across the 21 metrics below, Incyte Corporation leads on 17 and Genmab A/S Sponsored ADR on 4.
Valuation
Profitability
| Metric | GMAB | INCY | Biotechnology median |
|---|---|---|---|
| Gross margin | 93.03% | 92.62% | 65.16% |
| Operating margin | 25.95% | 30.56% | 0.00% |
| Net margin | 19.08% | 27.71% | 0.00% |
| Free cash flow margin | (153.64%) | 32.48% | 0.00% |
| Return on equity | 14.00% | 30.67% | (57.72%) |
| Return on assets | 8.30% | 23.55% | (49.22%) |
| Return on invested capital | 6.99% | 60.50% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack